
Vyloy pioneers new era in metastatic gastric cancer treatment with Claudin 18.2 targeting
“Metastatic gastric cancer has been slow to make therapeutic progress due to the limitations of targeted therapies, and targeted therapies have underserved HER2-negative patients in particular. While Vyloy is notable for targeting a novel biomarker in …